Unjha Formulations Ltd () News & Corporate Actions | Announcements, Board Meetings, Splits, Bonuses, Rights Issues

{ "main_header": { "sid": 782664, "name": "Unjha Formul.", "stock_name": "Unjha Formul.", "full_name": "Unjha Formulations Ltd", "name_url": "stocks-analysis/unjha-formul", "exchange": 0, "exchangecode": "", "primexch": 0, "country_id": 34, "currency": "INR", "cmp": "24.25", "chg": 0.4, "chgp": "1.68%", "dir": 1, "prev_price": "23.85", "mcapval": "11.00 Cr", "mcap": "Micro Cap", "scripcode": 531762, "symbol": "", "ind_name": "Pharmaceuticals & Biotechnology", "ind_code": 4, "sector_id": 65, "indexname": "India SENSEX", "isin": "INE576D01015", "curr_date": "Aug 07, 03:30 PM", "curr_time": "21:40 PM", "last_traded_at": "Aug 07, 03:30 PM IST", "bse_nse_vol": "6.94 k", "exc_status": "Active", "traded_date": "Aug 07, 2026", "traded_date_str": "2026 08 07", "score": "", "scoreText": "", "Live": 0, "market_time": 0, "is_blur": 1, "is_blur_class": "blur-register-score-header", "is_blur_url": "https://www.marketsmojo.com/mojofeed/register?redirect=/stocks-analysis/unjha-formul-782664-0&utm_source=Spage_Header_Score", "mojoone": { "ismore": 0 } }, "news": { "results": [ { "title": "Unjha Formulations Falls 6.77%: Downgrade and Volatility Drive Weekly Decline", "link": "https://www.marketsmojo.com/news/stocks-in-action/unjha-formulations-falls-677-downgrade-and-volatility-drive-weekly-decline-4143393", "imagepath": "", "date": "2026-08-08 15:08:36", "description": " <div class=\"article-news-new\">\n <div class=\"article-container\">\n\n<div class=\"article-content\">\n <div class=\"highlight-box\">\n <h3>Key Events This Week</h3>\n <p><strong>3 Aug:</strong> Q1 FY27 results reveal modest recovery but underlying volatility concerns</p>\n <p><strong>6 Aug:</strong> Downgrade to Strong Sell by MarketsMOJO amid mixed technicals and flat financials</p>\n <p><strong>7 Aug:</strong> Week closes at Rs.24.25, down 6.77% despite Sensex gains</p>\n </div>\n\n <div class=\"stats-row\">\n <div class=\"stat-item\"><div class=\"stat-label\">Week Open</div><div class=\"stat-value\">Rs.26.01</div></div>\n <div class=\"stat-item\"><div class=\"stat-label\">Week Close</div><div class=\"stat-value\">Rs.24.25</div><div class=\"stat-change negative\">-6.77%</..." }, { "title": "Unjha Formulations Ltd Downgraded to Strong Sell Amid Mixed Technicals and Flat Financials", "link": "https://www.marketsmojo.com/news/stock-recommendation/unjha-formulations-ltd-downgraded-to-strong-sell-amid-mixed-technicals-and-flat-financials-4139317", "imagepath": "https://i.marketsmojo.com/newsimg/2026/8/UnjhaFormulatio_mojoScore_4139317.png", "date": "2026-08-06 08:09:43", "description": "Unjha Formulations Ltd has seen its investment rating downgraded from Sell to Strong Sell as of 5 August 2026, reflecting a complex interplay of technical, valuation, financial trend, and quality factors. Despite an attractive valuation and solid long-term returns, recent technical signals and flat quarterly financials have raised concerns among analysts, prompting a reassessment of the stock’s outlook." }, { "title": "Are Unjha Formulations Ltd latest results good or bad?", "link": "https://www.marketsmojo.com/news/result-analysis/are-unjha-formulations-ltd-latest-results-good-or-bad-4136137", "imagepath": "", "date": "2026-08-04 19:19:50", "description": "Unjha Formulations Ltd's latest financial results for Q1 FY27 reflect a complex operational landscape marked by both recovery and ongoing challenges. The company reported a net profit of ₹0.16 crores, recovering from a loss of ₹0.74 crores in the previous quarter, indicating a quarter-on-quarter improvement in profitability. However, this recovery is juxtaposed with a year-on-year revenue decline of 8.31%, with net sales recorded at ₹3.31 crores, suggesting potential demand weaknesses or competitive pressures in its niche market of Isabgol formulations.\n\nThe operating margin for the quarter stood at 6.04%, a significant contraction from 11.63% in the same quarter last year, highlighting ongoing margin pressures likely due to rising operational expenses, including a notable 61.54% increase in employee costs. This situation underscores the challenges Unjha Formulations faces in maintaining profitability amids..." }, { "title": "Unjha Formulations Q1 FY27: Modest Recovery Masks Underlying Volatility Concerns", "link": "https://www.marketsmojo.com/news/result-analysis/unjha-formulations-q1-fy27-modest-recovery-masks-underlying-volatility-concerns-4134182", "imagepath": "https://i.marketsmojo.com/newsimg/2026/8/UnjhaFormulatio_quaterlyResult_4134182.png", "date": "2026-08-03 21:16:23", "description": "Unjha Formulations Ltd., a Gujarat-based pharmaceutical company specialising in Isabgol (Psyllium) formulations, reported a marginal improvement in its Q1 FY27 results, posting a net profit of ₹0.16 crores, a modest recovery from the loss-making Q4 FY26. However, the company's performance remains marred by persistent volatility and declining year-on-year metrics, raising questions about its operational stability and growth trajectory." }, { "title": "Unjha Formulations Surges 9.24%: 3 Key Drivers Behind the Rally", "link": "https://www.marketsmojo.com/news/stocks-in-action/unjha-formulations-surges-924-3-key-drivers-behind-the-rally-4131703", "imagepath": "", "date": "2026-08-01 15:09:16", "description": " <div class=\"article-news-new\">\n <div class=\"article-container\">\n\n<div class=\"article-content\">\n <div class=\"highlight-box\">\n <h3>Key Events This Week</h3>\n <p><strong>27 Jul:</strong> Stock opens week at Rs.24.74, gaining 3.91%</p>\n <p><strong>29 Jul:</strong> New 52-week high at Rs.28.76</p>\n <p><strong>30 Jul:</strong> Further 52-week high at Rs.29.5</p>\n <p><strong>31 Jul:</strong> Valuation metrics improve; stock closes at Rs.26.01</p>\n </div>\n\n <div class=\"stats-row\">\n <div class=\"stat-item\"><div class=\"stat-label\">Week Open</div><div class=\"stat-value\">Rs.24.74</div></div>\n <div class=\"stat-item\"><div class=\"stat-label\">Week Close</div><div class=\"stat-value\">Rs.26.01</div><div class=\"stat-change positive\">+5.12%</d..." }, { "title": "Unjha Formulations Ltd Valuation Shifts Signal Renewed Price Attractiveness", "link": "https://www.marketsmojo.com/news/stocks-in-action/unjha-formulations-ltd-valuation-shifts-signal-renewed-price-attractiveness-4129442", "imagepath": "https://i.marketsmojo.com/newsimg/2026/7/UnjhaFormulatio_valuationdot_4129442.png", "date": "2026-07-31 08:00:41", "description": "Unjha Formulations Ltd has witnessed a notable improvement in its valuation parameters, shifting from a very attractive to an attractive rating, signalling a positive change in price attractiveness amid a challenging pharmaceuticals sector. This micro-cap stock’s recent performance and valuation metrics merit close attention from investors seeking value in the Pharmaceuticals & Biotechnology space." }, { "title": "Broad-Based Technical Strength Lifts Unjha Formulations Ltd to 52-Week High of Rs 29.5", "link": "https://www.marketsmojo.com/news/stocks-in-action/unjha-formulations-ltd-hits-new-52-week-high-at-rs295-4128638", "imagepath": "https://i.marketsmojo.com/newsimg/2026/7/UnjhaFormulatio_priceRelatedfactors_4128638.png", "date": "2026-07-30 10:36:16", "description": "With a decisive surge to Rs 29.5 on 30 Jul 2026, Unjha Formulations Ltd has reached a fresh 52-week high, marking a significant milestone in its price momentum. This rally comes after a sustained four-day gain, delivering a 23.9% return in that period and outpacing its sector by over 7% today alone." }, { "title": "Broad-Based Technical Strength Lifts Unjha Formulations Ltd to 52-Week High of Rs 28.76", "link": "https://www.marketsmojo.com/news/stocks-in-action/unjha-formulations-ltd-hits-new-52-week-high-at-rs2876-4125976", "imagepath": "https://i.marketsmojo.com/newsimg/2026/7/UnjhaFormulatio_priceRelatedfactors_4125976.png", "date": "2026-07-29 11:41:08", "description": "With a decisive surge to Rs 28.76 on 29 Jul 2026, Unjha Formulations Ltd has reached a fresh 52-week high, propelled by a confluence of bullish technical indicators and sustained price momentum over recent sessions." }, { "title": "Unjha Formulations Ltd Upgraded to Sell on Technical Improvements Despite Flat Financials", "link": "https://www.marketsmojo.com/news/stock-recommendation/unjha-formulations-ltd-upgraded-to-sell-on-technical-improvements-despite-flat-financials-4094560", "imagepath": "https://i.marketsmojo.com/newsimg/2026/7/UnjhaFormulatio_mojoScore_4094560.png", "date": "2026-07-09 08:11:21", "description": "Unjha Formulations Ltd has seen its investment rating upgraded from Strong Sell to Sell as of 8 July 2026, driven primarily by a shift in technical indicators despite persistent fundamental challenges. The pharmaceutical micro-cap’s recent price action and technical signals have improved, prompting a reassessment of its market stance, even as financial trends remain subdued and valuation metrics present a mixed picture." } ], "total": 154, "sid": "782664", "stock_news_url": "https://www.marketsmojo.com/news/unjha-formulations-782664" }, "announcements": [ { "caption": "Publish Audited Financial Results For The Quarter And Year Ended As On 30/06/2026", "datetime": "05-Aug-2026", "details": "REG 33 (3) OF SEBI (LODR) ACT 2015", "source": "BSE" }, { "caption": "Board Meeting Outcome for Approval Of Un-Audited Financial Results Of The Company For First Quarter Ended On 30Th June 2026 And Out Come Of Board Meeting Held On 3Rd August 2026", "datetime": "03-Aug-2026", "details": "Regulation 33 of the SEBO(LODR) Act 2015", "source": "BSE" }, { "caption": "Approval Of Un-Audited Financial Results Of The Company For First Quarter Ended On 30Th June 2026 And Out Come Of Board Meeting Held On 3Rd August 2026", "datetime": "03-Aug-2026", "details": "Regulation 33 of SEBI(LODR) Act 2015", "source": "BSE" } ], "corporate_actions": [ { "img": "board-meeting.svg", "title": "BOARD MEETING", "msg": "<span>No</span> Upcoming Board Meetings", "data": [] }, { "img": "dividend.svg", "title": "DIVIDEND", "msg": "No <strong>Dividend</strong> history available", "data": [] }, { "img": "splits.svg", "title": "SPLITS", "msg": "No <strong>Splits</strong> history available", "data": [] }, { "img": "bonus.svg", "title": "BONUS", "msg": "No <strong>Bonus</strong> history available", "data": [] }, { "img": "rights-issues.svg", "title": "RIGHTS", "msg": "No <strong>Rights</strong> history available", "data": [] } ] }

Key Events This Week

3 Aug: Q1 FY27 results reveal modest recovery but underlying volatility concerns

6 Aug: Downgrade to Strong Sell by MarketsMOJO amid mixed technicals and flat financials

7 Aug: Week closes at Rs.24.25, down 6.77% despite Sensex gains

-6.77%Read full news article

Unjha Formulations Ltd Downgraded to Strong Sell Amid Mixed Technicals and Flat Financials

2026-08-06 08:09:43

Unjha Formulations Ltd has seen its investment rating downgraded from Sell to Strong Sell as of 5 August 2026, reflecting a complex interplay of technical, valuation, financial trend, and quality factors. Despite an attractive valuation and solid long-term returns, recent technical signals and flat quarterly financials have raised concerns among analysts, prompting a reassessment of the stock’s outlook.

Read full news article

Are Unjha Formulations Ltd latest results good or bad?

2026-08-04 19:19:50

Unjha Formulations Ltd's latest financial results for Q1 FY27 reflect a complex operational landscape marked by both recovery and ongoing challenges. The company reported a net profit of ₹0.16 crores, recovering from a loss of ₹0.74 crores in the previous quarter, indicating a quarter-on-quarter improvement in profitability. However, this recovery is juxtaposed with a year-on-year revenue decline of 8.31%, with net sales recorded at ₹3.31 crores, suggesting potential demand weaknesses or competitive pressures in its niche market of Isabgol formulations. The operating margin for the quarter stood at 6.04%, a significant contraction from 11.63% in the same quarter last year, highlighting ongoing margin pressures likely due to rising operational expenses, including a notable 61.54% increase in employee costs. This situation underscores the challenges Unjha Formulations faces in maintaining profitability amids...

Read full news article

Unjha Formulations Q1 FY27: Modest Recovery Masks Underlying Volatility Concerns

2026-08-03 21:16:23

Unjha Formulations Ltd., a Gujarat-based pharmaceutical company specialising in Isabgol (Psyllium) formulations, reported a marginal improvement in its Q1 FY27 results, posting a net profit of ₹0.16 crores, a modest recovery from the loss-making Q4 FY26. However, the company's performance remains marred by persistent volatility and declining year-on-year metrics, raising questions about its operational stability and growth trajectory.

Read full news article

Unjha Formulations Surges 9.24%: 3 Key Drivers Behind the Rally

2026-08-01 15:09:16

Key Events This Week

27 Jul: Stock opens week at Rs.24.74, gaining 3.91%

29 Jul: New 52-week high at Rs.28.76

30 Jul: Further 52-week high at Rs.29.5

31 Jul: Valuation metrics improve; stock closes at Rs.26.01

+5.12%Read full news article

Unjha Formulations Ltd Valuation Shifts Signal Renewed Price Attractiveness

2026-07-31 08:00:41

Unjha Formulations Ltd has witnessed a notable improvement in its valuation parameters, shifting from a very attractive to an attractive rating, signalling a positive change in price attractiveness amid a challenging pharmaceuticals sector. This micro-cap stock’s recent performance and valuation metrics merit close attention from investors seeking value in the Pharmaceuticals & Biotechnology space.

Read full news article

Broad-Based Technical Strength Lifts Unjha Formulations Ltd to 52-Week High of Rs 29.5

2026-07-30 10:36:16

With a decisive surge to Rs 29.5 on 30 Jul 2026, Unjha Formulations Ltd has reached a fresh 52-week high, marking a significant milestone in its price momentum. This rally comes after a sustained four-day gain, delivering a 23.9% return in that period and outpacing its sector by over 7% today alone.

Read full news article

Broad-Based Technical Strength Lifts Unjha Formulations Ltd to 52-Week High of Rs 28.76

2026-07-29 11:41:08

With a decisive surge to Rs 28.76 on 29 Jul 2026, Unjha Formulations Ltd has reached a fresh 52-week high, propelled by a confluence of bullish technical indicators and sustained price momentum over recent sessions.

Read full news article

Unjha Formulations Ltd Upgraded to Sell on Technical Improvements Despite Flat Financials

2026-07-09 08:11:21

Unjha Formulations Ltd has seen its investment rating upgraded from Strong Sell to Sell as of 8 July 2026, driven primarily by a shift in technical indicators despite persistent fundamental challenges. The pharmaceutical micro-cap’s recent price action and technical signals have improved, prompting a reassessment of its market stance, even as financial trends remain subdued and valuation metrics present a mixed picture.

Read full news article

View All News